About this episode
<p>Existing drugs can sometimes be repurposed to treat rare diseases. But making that match can be hard — and the financial incentives are weak. Guest host Steve Levitt tries to solve the puzzle.</p> <p> </p> <ul> <li><strong>SOURCES:</strong> <ul> <li><a href="https://faculty-directory.dartmouth.edu/christopher-snyder" rel="noopener noreferrer">Chris Snyder</a>, professor of economics at Dartmouth College.</li> <li><a href="https://www.med.upenn.edu/apps/faculty/index.php/g275/p8205911" rel="noopener noreferrer">David Fajgenbaum</a>, co-founder and president of Every Cure, physician-scientist at the University of Pennsylvania.</li> <li><a href="https://www.linkedin.com/in/heather-stone-51a94a49/" rel="noopener noreferrer">Heather Stone</a>, health science policy analyst at the Food & Drug Administration.</li> <li><a href="https://www.linkedin.com/in/s-chethik/" rel="noopener noreferrer">Sarrin Chethik</a>, senior policy analyst at the Market Shaping Accelerator.</li> </ul></li> </ul> <p> </p> <ul> <li><strong>RESOURCES:</strong> <ul> <li><a href="https://amzn.to/40inncE" rel="noopener noreferrer"><i>Chasing My Cure: A Doctor's Race to Turn Hope into Action; A Memoir</i></a><i>, </i>by David Fajgenbaum (2019).</li> <li><a href="https://amzn.to/4tOfJEA" rel="noopener noreferrer"><i>Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases</i></a><i>, </i>by Michael Kremer and Rachel Glennerster (2016).</li> <li><a href="https://www.marketshapingaccelerator.org/" rel="noopener noreferrer">Market Shaping Accelerator</a>.</li> <li><a href="https://cure.ncats.io/create" rel="noopener noreferrer">CURE ID Registry</a>.</li> </ul></li> </ul><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>